Quotient Limited (QTNT) Issues Quarterly Earnings Results

Quotient Limited (NASDAQ:QTNT) posted its quarterly earnings results on Monday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.55), Bloomberg Earnings reports. The firm had revenue of $6.83 million for the quarter, compared to analysts’ expectations of $5.70 million. Quotient Limited had a negative return on equity of 13,050.41% and a negative net margin of 381.66%.

Shares of Quotient Limited (NASDAQ QTNT) traded down 2.01% during trading on Thursday, hitting $3.91. The company had a trading volume of 142,115 shares. The company’s 50 day moving average is $5.92 and its 200 day moving average is $6.61. Quotient Limited has a 1-year low of $3.75 and a 1-year high of $8.64. The firm’s market capitalization is $56.21 million.

A number of equities analysts have issued reports on the company. ValuEngine upgraded Quotient Limited from a “strong sell” rating to a “sell” rating in a report on Friday, June 30th. Zacks Investment Research upgraded Quotient Limited from a “sell” rating to a “hold” rating in a report on Wednesday, May 17th.

In related news, insider D J. Paul E. Cowan sold 45,032 shares of Quotient Limited stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $6.57, for a total transaction of $295,860.24. Following the sale, the insider now directly owns 26,666 shares in the company, valued at $175,195.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider D J. Paul E. Cowan sold 9,420 shares of Quotient Limited stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $6.11, for a total value of $57,556.20. Following the sale, the insider now owns 26,666 shares in the company, valued at $162,929.26. The disclosure for this sale can be found here. Insiders have sold 165,612 shares of company stock worth $1,061,671 over the last 90 days. 29.00% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the stock. Northern Trust Corp purchased a new stake in Quotient Limited during the second quarter valued at $1,783,000. State Street Corp bought a new stake in Quotient Limited during the second quarter valued at approximately $1,728,000. Scholtz & Company LLC bought a new stake in Quotient Limited during the second quarter valued at approximately $939,000. FNY Partners Fund LP bought a new stake in Quotient Limited during the first quarter valued at approximately $636,000. Finally, Ameriprise Financial Inc. increased its stake in Quotient Limited by 5.2% in the second quarter. Ameriprise Financial Inc. now owns 1,829,895 shares of the company’s stock valued at $13,468,000 after buying an additional 90,057 shares during the period. Institutional investors own 38.97% of the company’s stock.

WARNING: This story was published by [[site]] and is owned by of [[site]]. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at [[permalink]].

About Quotient Limited

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.